Ignite Creation Date:
2024-07-17 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06480123
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-28
First Post:
2024-06-23
Brief Title:
Stem Cell Derived Exome for Treatment of Diabetic Foot
Sponsor:
Second Affiliated Hospital of Guangzhou Medical University
Organization:
Second Affiliated Hospital of Guangzhou Medical University
Study Overview
Official Title:
Skin Drug Prepared From Stem Cell Derived Exome for Treatment of Diabetic Foot a Phase II Clinical Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is designed to investigate the safety and efficacy of patients with diabetic foot by using stem cell derived exome
Detailed Description:
It is estimated that about 150 million people are suffering diabetes mellitus of whom more than 15 will develop foot ulcers or gangrene at some times so called diabetic foot The diabetic foot is very difficult to cure by traditional approaches
This phase I clinical trial is designed to assess the safety and theraputical benefit of the stem cell derived exome
This phase I clinical trial is designed to assess the safety and theraputical benefit of the stem cell derived exome
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None